Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward ...

Walmart will offer in‑store pickup of Eli Lilly’s discounted weight‑loss drug Zepbound, giving self‑pay customers easier, ...

Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a Chinese phase 3 trial. | Takeda tightened its pipeline in the third quarter.

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Recursion, Roche and Genentech unveiled the latest product of their nearly four-year artificial intelligence drug discovery collaboration. GSK ’s Blenrep was approved by the FDA for treatment of ...

A new drug-sales king has been crowned. Eli Lilly’s diabetes and weight-loss drug tirzepatide, marketed under the Mounjaro ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

Insmed stock surged Thursday as Argenx stock slipped. The top-notch biotech companies beat third-quarter calls.